iBio, Inc. (IBIO) News
Filter IBIO News Items
IBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IBIO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IBIO News From Around the Web
Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBioAchievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug and target discovery platform potentialSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity usin |
iBio Expands Pipeline with New Antibody AgreementAn update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and cardiometabolic disorders. This agreement involves an upfront payment of $750,000 in stock and potential milestone payments up to $28 million. The collaboration enables iBio to expand its treatment programs, leveraging its proprietary technology for developing a bispecific antibody targeting myostatin/acti |
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed PlatformOn Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In March, iBio collaborated with AstralBio to discover, engineer, and develop antibodies to treat obesity and other cardiometabolic conditions. The antibody, now named IBIO-600, was identified by AstralBio using iBio’s proprietary technology stack. It was designed for subcutaneous administration and has t |
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBioBuilding on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Regain, Potentially Enabling Less Frequent Dosing than Current Obesity TreatmentsSAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development pr |
iBio Strengthens Board with Appointment of Two New Independent DirectorsSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. “These appointments expand and strengthen our board to align with iBio’s vision of becoming a next-generation antibody discovery and development company with a robust clinical pi |
iBio Reports Fiscal First Quarter 2025 Financial ResultsAdvanced myostatin program with dosing underway in non-human primate studySAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progre |
iBio and AstralBio Provide Update on Myostatin Program for ObesityLead molecule identified with potential extended half-life and subcutaneous dosingSAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Follo |
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateSAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. “Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics, |
iBio to Participate in Upcoming Investor ConferencesSAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences. Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. |
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business DevelopmentLife sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targetsSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business development. Ms. Sarno brings more than 25 years of business development and strategic experience in the life sciences industry |